NCT06650332 2024-10-21
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
Clinical Trials
1 trialsMetastatic HER2 Positive Gastroesophageal Junction Cancer × disitamab vedotin × Gastrointestinal × Clear all